Diagnostic Approach to Suspected Sarcoidosis

1. Core Diagnostic Requirements

• The diagnosis of sarcoidosis requires (a) a compatible clinical and radiologic presentation, (b) histopathologic evidence of noncaseating granulomas, and (c) rigorous exclusion of alternative causes such as infections, malignancy, and other granulomatous diseases. – American Thoracic Society (ATS) recommendation. 1

2. High‑Probability Clinical Syndromes that May Obviate Biopsy

• Presence of Löfgren’s syndrome (bilateral hilar adenopathy + erythema nodosum and/or periarticular arthritis), lupus pernio, or Heerfordt’s syndrome makes sarcoidosis highly probable; the ATS advises that lymph‑node biopsy is not required in these patients, provided close clinical follow‑up is ensured. – ATS recommendation; strong recommendation. [2][1]

3. Imaging Findings Supporting the Diagnosis

• Chest CT is the first‑line imaging modality and should be used to identify bilateral hilar lymphadenopathy, perilymphatic nodules, peribronchial thickening, upper‑lobe or diffuse infiltrates, and the presence of two or more enlarged extrathoracic lymph nodes. – ATS guidance. 3

4. Ancillary Bronchoalveolar Lavage (BAL) Information

• BAL showing lymphocytosis or an elevated CD4⁺:CD8⁺ ratio can aid in excluding infectious or malignant mimics when tissue sampling is pursued. – ATS guidance. 3

5. Histopathologic Criteria (When Tissue Is Obtained)

• Specimens must demonstrate noncaseating granulomas (minimal focal necrosis is acceptable), negative stains and cultures for microorganisms, and additional features that help differentiate sarcoidosis from its mimics. – ATS criteria. [1][3]

6. Mandatory Exclusion of Alternative Granulomatous Disorders

• Chronic beryllium disease – obtain a beryllium lymphocyte proliferation test in exposed individuals.
• Hypersensitivity pneumonitis – assess relevant environmental/occupational exposures.
• Drug‑induced granulomatosis – consider agents such as TNF‑α antagonists, immune‑checkpoint inhibitors, and interferons.
• Granulomatosis with polyangiitis – test for MPO‑ANCA and PR3‑ANCA antibodies.
• IgG4‑related disease – measure serum IgG4 levels and IgG4:IgG ratio.
• Common variable immune deficiency – appropriate immunologic work‑up. – ATS recommendation. 3

7. Baseline Laboratory Screening for Organ Involvement

*All baseline tests are endorsed by the ATS. [2][1]

8. Cardiac Screening Protocol (Extracardiac Disease without Cardiac Symptoms)

• Perform a baseline resting ECG in all patients. – ATS recommendation. [2][1]
• The ATS advises against routine transthoracic echocardiography (TTE) or Holter monitoring for screening; these may be used selectively when clinical suspicion exists. – ATS recommendation. [2][1]
• If cardiac sarcoidosis is suspected, cardiac MRI with gadolinium is the preferred diagnostic test; when MRI is unavailable, a dedicated cardiac PET scan is recommended over TTE. – ATS recommendation. 2

9. Common Diagnostic Pitfalls to Avoid

• Do not rely solely on ACE levels for diagnosis due to limited sensitivity and specificity. – ATS caution.
• Recognize drug‑induced sarcoid‑like reactions in patients receiving TNF‑α antagonists, immune‑checkpoint inhibitors, or interferons. – ATS warning. 3
• New‑onset third‑degree atrioventricular block in young or middle‑aged adults should raise suspicion for cardiac sarcoidosis. – ATS warning. 3
• Ensure diligent clinical follow‑up for patients diagnosed without tissue confirmation to monitor for disease evolution or alternative diagnoses. – ATS recommendation. [2][1]

Sarcoidosis Diagnosis and Management

Diagnostic Criteria and Tests

• The American Thoracic Society recommends that the diagnosis of sarcoidosis requires a compatible clinical and radiologic presentation, histopathologic evidence of noncaseating granulomas, and exclusion of alternative diagnoses that can mimic sarcoidosis 4
• Löfgren's syndrome, characterized by bilateral hilar adenopathy with erythema nodosum and/or periarticular arthritis, is a highly probable feature of sarcoidosis 5
• Characteristic physical findings, including lupus pernio, uveitis, optic neuritis, and erythema nodosum, can support the diagnosis of sarcoidosis 4, 5
• Distinctive imaging findings, such as bilateral hilar adenopathy on chest X-ray, CT, or PET, perilymphatic nodules on chest CT, and gadolinium enhancement on CNS MRI, can aid in the diagnosis of sarcoidosis 4, 5
• Laboratory abnormalities, like hypercalcemia or hypercalciuria with abnormal vitamin D metabolism, and elevated ACE levels (>50% above upper limit of normal) can also be present in sarcoidosis 5
• Chest imaging, including X-ray and CT scans, is a first-line diagnostic test and may show bilateral hilar lymphadenopathy and/or parenchymal infiltrates 5
• Tissue biopsy is essential for confirming noncaseating granulomas, and site selection should be based on accessibility and clinical manifestations 4
• Bronchoalveolar lavage (BAL) can show lymphocytosis or elevated CD4:CD8 ratio and is useful for excluding infections or malignancy 4

Treatment and Management

• The American College of Chest Physicians recommends treatment for sarcoidosis when there is a significant impact on quality of life 6
• Methotrexate is a first-choice steroid-sparing agent for the treatment of sarcoidosis 6
• Azathioprine is particularly useful for hepatic and pulmonary involvement in sarcoidosis 6
• Mycophenolate is an alternative for interstitial lung disease in sarcoidosis 6
• TNF inhibitors, such as infliximab and adalimumab, can be used for refractory cases of sarcoidosis 6
• Intravenous immunoglobulin (IVIg) may be considered for persistent small-fiber neuropathy in sarcoidosis 6

Common Pitfalls to Avoid

• Inadequate exclusion of alternative diagnoses, particularly infections, can lead to misdiagnosis of sarcoidosis 4
• Overreliance on ACE levels for diagnosis can result in false negatives or positives due to limited sensitivity and specificity 5
• Insufficient monitoring for extrapulmonary manifestations can lead to delayed diagnosis and treatment of sarcoidosis 6
• Premature discontinuation of therapy can lead to relapse of sarcoidosis 6
• Failure to recognize cardiac involvement can result in significant mortality risk in sarcoidosis 6